APREHealthcare · BiotechnologyThe 4 Wall Street analysts covering Aprea Therapeutics, Inc. hold a median 12-month price target of $4 — +522.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Aprea Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (8): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on APRE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +522.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $6.00 → $3.00 |
| 14 May 2026 | Wedbush | Maintains | Outperform | $7.00 → $6.00 |
| 14 May 2026 | Wedbush | Maintains | Outperform | — |
| 7 May 2026 | Oppenheimer | Initiates | Outperform | $5.00 |
| 7 May 2026 | Oppenheimer | Initiates | Outperform | — |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 10 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 29 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | Wedbush | Reiterates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2024 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APRE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 1% of US stocks
Cheaper than 89% of US stocks
Cheaper than 56% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aprea Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aprea Therapeutics announced its second quarter 2026 financial results. The company reported that enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances.
Why it matters — APRE watchers would care because accelerating enrollment signals continued momentum for the company's lead clinical program, APR-1051.
Aprea Therapeutics provided an update on the ongoing Phase 1 dose escalation ACESOT-1051 trial of its WEE1 inhibitor APR-1051, reporting accelerating enrollment and plans to expand the drug's evaluation into uterine serous carcinoma, platinum-resistant ovarian cancer, HPV-positive head and neck cancer, and colorectal cancer. The company anticipates presenting the next clinical data update at a medical meeting in Q4 2026.
Why it matters — APRE watchers would care because the company is signaling continued clinical progress and an expanded development strategy for APR-1051, its lead pipeline candidate, with a key data catalyst expected in late 2026.
The 4 Wall Street analysts covering Aprea Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $1.2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Aprea Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aprea Therapeutics, Inc. 44 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Aprea Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +522.5% from the last close, and Ticker Nerd's factor model ranks Aprea Therapeutics, Inc. 44 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aprea Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $5 over the next 12 months.
Aprea Therapeutics, Inc. returned -59.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Clear Creek Independent School District is an award-winning pre-K through 12th-grade public school district serving the Greater Houston area in Texas. It provides foundational education to approximately 38,000 students across 100 square miles spanning 13 municipalities in Harris and Galveston counties, making it the 29th largest district in Texas.
The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Aprea Therapeutics Announces Second Quarter 2026 Financial Results". Aprea Therapeutics announced its second quarter 2026 financial results. The company reported that enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances.
Clear Creek Independent School District is an award-winning pre-K through 12th-grade public school district serving the Greater Houston area in Texas. It provides foundational education to approximately 38,000 students across 100 square miles spanning 13 municipalities in Harris and Galveston counties, making it the 29th largest district in Texas. The district operates multiple high schools, including Clear Brook, Clear Creek, Clear Falls, Clear Lake, Clear Springs, and Clear View, alongside elementary and intermediate schools, with a focus on academic excellence, specialized programs, and partnerships with local businesses and higher education institutions to enhance learning experiences. Special services support each student's unique talents and interests, fostering personal success. Financial services manage budgeting, payroll, taxes, cash investments, purchasing, and contract administration to sustain educational operations. The district maintains a balanced general fund budget and reports key financial data, including unclaimed property, ensuring transparency for stakeholders. Headquartered in League City, Texas, Clear Creek Independent School District emphasizes a spirit of exploration and community desirability for families.
CEO Dr. Oren Gilad Ph.D. · 8 employees · United States · https://aprea.com